-+ 0.00%
-+ 0.00%
-+ 0.00%

EU approves Merck's Keytruda-Padcev regimen for muscle-invasive bladder cancer

PUBT·10/21/2026 10:46:11
Listen to the news
EU approves Merck's Keytruda-Padcev regimen for muscle-invasive bladder cancer
  • European Commission approved Merck’s Keytruda with Padcev before and after surgery for adults with resectable muscle-invasive bladder cancer, regardless of cisplatin eligibility.
  • The Phase 3 KEYNOTE-B15 trial showed a 47% reduction in disease progression, recurrence or death risk versus chemotherapy and surgery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021594617) on October 21, 2026, and is solely responsible for the information contained therein.